{"filing":{"accession_number":"0001140361-26-028208","cik":"0001658247","ticker":"CRNX","company_name":"Crinetics Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-10","report_date":null,"primary_document":"crnx-20260706.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1658247/000114036126028208/crnx-20260706.htm"},"events":[{"id":17299,"run_id":15481,"accession_number":"0001140361-26-028208","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Crinetics Pharmaceuticals entered into a merger agreement dated July 6, 2026, whereby Vertex Pharmaceuticals will acquire Crinetics through a merger of Merger Sub into the Company, with Crinetics surviving as a wholly owned subsidiary of Vertex. The transaction constitutes a material acquisition and change of control requiring stockholder approval.","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-07-10","form":"8-K","submitted_at":null,"items":[{"id":15683,"accession_number":"0001140361-26-028208","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on entry into a merger agreement dated July 6, 2026, whereby Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals through a merger of Merger Sub into the Company, with the Company surviving as a wholly owned subsidiary of Parent. This is a material acquisition and change of control transaction. While the Item 1.01 section also describes ancillary non-compete agreements with key executives, the principal event is the merger itself, which is explicitly identified as the \"Material Definitive Agreement\" in the Item heading.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T20:02:38.862402+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15684,"accession_number":"0001140361-26-028208","item_number":"5.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 5.02 incorporates by reference Item 1.01, which addresses material acquisitions and mergers. The prose discloses a proposed merger transaction between Crinetics Pharmaceuticals and \"Parent\" (Vertex Pharmaceuticals, based on the investor relations domain reference), requiring stockholder approval and proxy filing. This is a material change-of-control transaction, not a routine executive departure, appointment, or compensation arrangement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T20:02:38.862402+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15683,"accession_number":"0001140361-26-028208","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on entry into a merger agreement dated July 6, 2026, whereby Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals through a merger of Merger Sub into the Company, with the Company surviving as a wholly owned subsidiary of Parent. This is a material acquisition and change of control transaction. While the Item 1.01 section also describes ancillary non-compete agreements with key executives, the principal event is the merger itself, which is explicitly identified as the \"Material Definitive Agreement\" in the Item heading.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T20:02:38.862402+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-07-10"},{"id":15684,"accession_number":"0001140361-26-028208","item_number":"5.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 5.02 incorporates by reference Item 1.01, which addresses material acquisitions and mergers. The prose discloses a proposed merger transaction between Crinetics Pharmaceuticals and \"Parent\" (Vertex Pharmaceuticals, based on the investor relations domain reference), requiring stockholder approval and proxy filing. This is a material change-of-control transaction, not a routine executive departure, appointment, or compensation arrangement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T20:02:38.862402+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-07-10"}]}